Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows

Core Insights - Novo Nordisk invested nearly $500 million in U.S. advertising for its GLP-1 drugs Wegovy and Ozempic during the first nine months of 2025, which is more than double the amount spent by Eli Lilly on its competing products [1] Company Summary - Novo Nordisk's advertising expenditure for GLP-1 drugs indicates a strong commitment to market presence and brand awareness in the competitive landscape of diabetes and obesity treatments [1] - Eli Lilly's lower advertising spend suggests a different strategic approach in promoting its rival medications, potentially impacting market share dynamics [1]